Vericel Corporation
Vericel Corporation (VCEL) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · VCEL · as of Sep 30, 2025
Ownership Breakdown
253
Institutional Holders
▼ 26 vs Q2
$1.67B
Total Inst. Value
▼ $678.10M vs Q2
51.07M
Shares Outstanding
freeFloat 98.76%
53.13M
13F Shares Held
▼ 2.10M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
VCEL largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
BLACKROCK, INC. biological products, (no diagnostic substances) | 7.57M | 15.03% | 15.03% | $238.20B | Nov 12, 2025 | ▼ 9.3K |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 3.52M | 6.98% | 6.98% | $110.64B | Nov 7, 2025 | ▼ 47.8K |
STATE STREET CORP biological products, (no diagnostic substances) | 2.81M | 5.57% | 5.57% | $88.34B | Nov 14, 2025 | ▲ 371.8K |
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC biological products, (no diagnostic substances) | 2.21M | 4.39% | 4.39% | $69.58B | Nov 12, 2025 | ▲ 1.05M |
CONESTOGA CAPITAL ADVISORS, LLC biological products, (no diagnostic substances) | 2.18M | 4.32% | 4.32% | $68.46B | Oct 24, 2025 | ▼ 288.3K |
FMR LLC biological products, (no diagnostic substances) | 2.02M | 4.01% | 4.01% | $63.50B | Nov 13, 2025 | ▼ 456.3K |
BROWN CAPITAL MANAGEMENT LLC biological products, (no diagnostic substances) | 1.95M | 3.87% | 3.87% | $61.40B | Nov 4, 2025 | ▼ 861.0K |
GENEVA CAPITAL MANAGEMENT LLC biological products, (no diagnostic substances) | 1.95M | 3.86% | 3.86% | $61.25B | Nov 13, 2025 | ▲ 161.4K |
CONGRESS ASSET MANAGEMENT CO /MA biological products, (no diagnostic substances) | 1.49M | 2.97% | 2.97% | $47.04B | Oct 10, 2025 | ▼ 247.7K |
GW&K INVESTMENT MANAGEMENT, LLC biological products, (no diagnostic substances) | 1.29M | 2.56% | 2.56% | $40.60B | Nov 12, 2025 | ▼ 124.4K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
19
Increased
+3.54M shares1
New Positions
first time holders29
Decreased
−4.28M shares0
Sold Out
fully exitedNet shares change (top 50)
738.8K
+3.54M / −4.28M
Net new holders
-9
1 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
VCEL insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
32
Buy transactions
9
Sell transactions
3.56
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Hopper Jonathan Mark Chief Medical Officer | Jun 2, 2026 | Sale | 4,375 | $35.00 | $153.1K | 75.8K | Form 4 ↗ |
MCLAUGHLIN KEVIN F director | May 13, 2026 | Sale | 3,500 | $32.82 | $114.9K | 18.3K | Form 4 ↗ |
MCLAUGHLIN KEVIN F director | May 13, 2026 | Sale | 3,500 | $32.83 | $114.9K | 18.3K | Form 4 ↗ |
Wotton Paul K director | May 11, 2026 | Sale | 2,500 | $33.05 | $82.6K | 26.3K | Form 4 ↗ |
Wotton Paul K director | May 11, 2026 | Sale | 7,500 | $32.64 | $244.8K | 18.8K | Form 4 ↗ |
Mara Joseph Anthony Jr Chief Financial Officer | May 7, 2026 | Sale | 5,000 | $40.50 | $202.5K | 21.0K | Form 4 ↗ |
SIEGAL JONATHAN Principal Accounting Officer | May 6, 2026 | Sale | 3,433 | $38.00 | $130.5K | 2.5K | Form 4 ↗ |
SIEGAL JONATHAN Principal Accounting Officer | May 7, 2026 | Sale | 1,422 | $40.50 | $57.6K | 1.1K | Form 4 ↗ |
MCLAUGHLIN KEVIN F director | Apr 29, 2026 | Award | 8,000 | $33.43 | $267.4K | 8.0K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Vericel Corporation (VCEL) is primarily owned by institutional investors, who hold approximately 100.0% of total shares outstanding. Company insiders own approximately 1.24%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of Vericel Corporation is BLACKROCK, INC., holding approximately 7.57 million shares — equal to 15.03% of outstanding shares — as of September 30, 2025.
A total of 253 institutional investors currently hold VCEL stock, with a combined institutional value of approximately $1.67 billion as of the most recent 13F filing period.
Frequently asked questions
VCEL ownershipVericel Corporation (VCEL) is primarily owned by institutional investors, who hold approximately 100.0% of shares. The largest shareholder is BLACKROCK, INC. with a 15.03% stake. Company insiders hold 1.24%. Data sourced from SEC Form 13F as of September 30, 2025.